Distinct Markers of Discordant Treatment Response to Lifestyle Intervention in MASLD, Independent of Weight Loss.

ABSTRACT: Background/Objectives: Weight loss is the primary therapy for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the proportion and factors influencing therapeutic changes in the liver condition contrary to weight loss remain unclear. Methods: This observational cohort study spanned between January 2015 and January 2024, with a 48-week lifestyle modification until January 2025. The liver fat content (LFC) determined using MRI-PDFF and liver stiffness measurement (LSM) via 2D-SWE were assessed at baseline and 48 weeks. The weight loss target (WLT) was determined as a reduction of ≥3% in body weight for lean/normal-weight patients and ≥5% for patients who were overweight/obese. Results: Overall, 397 patients with MASLD (30.5% achieving WLT) were i

SUBMITTER: Luo L 

PROVIDER: S-EPMC12466973 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature